Principal Scientist Transporters at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Ph.D. in biology, toxicology, pharmacology, or related major, with 4+ years of experience in the ADMET field, or Master’s degree with 6+ years relevant ADMET experience
Demonstrated ability to mentor and grow team members
In-depth expertise in the field of drug transporters, with understanding of ADMET principles
Extensive hands-on experience with in vitro drug transporter assays, proven ability in independent experimental design and analysis, with exceptional critical thinking and problem-solving abilities
Excellent written and oral communication skills

Responsibilities

Provide scientific oversight and mentorship within the Transporter Group, fostering a mindset of scientific rigor, critical thinking, and creative problem-solving
Support program teams by proactively identifying transporter-mediated ADME risks; designing, executing, and interpreting data from critical experiments. Effectively communicate findings to teams, prepare and review regulatory source reports
Troubleshoot and optimize in vitro transporter assays and identify and implement novel experimental strategies to enhance clinical translation of pre-clinical data
Contribute to the strategic direction of the Transporter Group, expanding our science and staying current with literature. Publish and present at internal and external meetings

Skills

DMPK

ADME

Transporters

In Vitro Assays

In Vivo Studies

DDI

Pharmacokinetics

Drug Discovery

Drug Development

Quantitative Translation

Scientific Leadership

Mentorship

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free